 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H14N2O |
| Molar mass | 190.246 g·mol−1 |
| 3D model (JSmol) | |
| |
Indantadol (developmental code namesCHF-3381,V-3381) is adrug of the2-aminoindane family which was formerly being investigated as ananticonvulsant andneuroprotective and is now under development for the treatment ofneuropathic pain andchronic cough inEurope byVernalis and Chiesi.[1][2][3][4][5][6][7][8] It acts as acompetitive,reversible, and non-selectivemonoamine oxidase inhibitor,[5][6][9] and as a lowaffinity,non-competitiveNMDA receptor antagonist.[1][2][10] Apilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain inphase IIbclinical trials.[7][8][11][12]
